2,188 Shares in Regeneron Pharmaceuticals, Inc. $REGN Purchased by B.A. Schrock Wealth Management Inc.

Key Points

• B.A. Schrock Wealth Management purchased 2,188 Regeneron shares worth approximately $1.61 million in the third quarter. Institutional investors and hedge funds collectively own 83.31% of REGN.
• Analyst sentiment remains positive, with one Strong Buy, 21 Buy, and nine Hold ratings; Regeneron has a consensus rating of Moderate Buy and an average price target of $834.24.
• Regeneron reported quarterly earnings of $14.29 per share, exceeding estimates by $4.13, while revenue rose 16.7% year over year to $4.29 billion. The company also paid a quarterly dividend of $0.94 per share, yielding approximately 0.5% annually.

B.A. Schrock Wealth Management Inc. bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 2,188 shares of the biopharmaceutical company's stock, valued at approximately $1,608,000.

Several other institutional investors and hedge funds have also modified their holdings of REGN. Mather Group LLC. raised its position in Regeneron Pharmaceuticals by 10.0% in the 3rd quarter. Mather Group LLC. now owns 870 shares of the biopharmaceutical company's stock valued at $660,000 after purchasing an additional 79 shares during the last quarter. Fortitude Family Office LLC increased its stake in shares of Regeneron Pharmaceuticals by 67.9% in the third quarter. Fortitude Family Office LLC now owns 47 shares of the biopharmaceutical company's stock valued at $36,000 after buying an additional 19 shares in the last quarter. Seelaus Asset Management LLC increased its stake in shares of Regeneron Pharmaceuticals by 17.6% in the third quarter. Seelaus Asset Management LLC now owns 589 shares of the biopharmaceutical company's stock valued at $447,000 after buying an additional 88 shares in the last quarter. First Citizens Bank & Trust Co. bought a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at about $1,730,000. Finally, Signal Advisors Wealth LLC bought a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at about $201,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

REGN has been the topic of several research reports. Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Sunday, September 20th. Guggenheim raised their price objective on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a "buy" rating in a research report on Monday, August 3rd. BMO Capital Markets raised their price objective on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company an "outperform" rating in a research report on Wednesday, September 9th. Wells Fargo & Company boosted their target price on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an "equal weight" rating in a research note on Friday, July 31st. Finally, Royal Bank Of Canada boosted their target price on shares of Regeneron Pharmaceuticals from $737.00 to $810.00 and gave the stock a "sector perform" rating in a research note on Thursday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $834.24.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Kathryn Guarini sold 400 shares of the company's stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $340,000.00. Following the completion of the sale, the director owned 603 shares of the company's stock, valued at approximately $512,550. This represents a 39.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Zoghbi sold 800 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the completion of the sale, the director owned 1,703 shares in the company, valued at approximately $1,362,400. This trade represents a 31.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 3,946 shares of company stock worth $3,302,458. 6.97% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $778.36 on Thursday. The firm's 50 day moving average price is $791.11 and its two-hundred day moving average price is $720.89. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. Regeneron Pharmaceuticals, Inc. has a 52-week low of $564.00 and a 52-week high of $859.34. The stock has a market cap of $80.14 billion, a PE ratio of 19.24, a PEG ratio of 1.30 and a beta of 0.16.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company had revenue of $4.29 billion during the quarter, compared to analysts' expectations of $3.82 billion. During the same quarter in the previous year, the company posted $12.81 EPS. The business's revenue for the quarter was up 16.7% compared to the same quarter last year. As a group, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 47.93 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were issued a dividend of $0.94 per share. The ex-dividend date was Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals's payout ratio is currently 9.29%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron's marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.